Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

36

Revenue 2017

Xtandi

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Xtandi was produced by Astellas.

Astellas signs up to immuno-oncology deal

Astellas signs up to immuno-oncology deal Astellas currently only has a small cancer pipeline with its main marketed product being the prostate cancer drug Xtandi (enzalutamide).

Valeant and Shire said to be evaluating potential Salix bids

Valeant and Shire said to be evaluating potential Salix bids drugs such as Johnson &Johnson's Zytiga (abiraterone) and Astellas/Medivation's Xtandi (enzalutamide) - but Valeant believes it can revitalise the product.

Personalised cancer medicines showcased in BBC investigation

Personalised cancer medicines showcased in BBC investigation Astellas and Medivation's advanced prostate cancer drug Xtandi (enzalutamide) was highlighted being used with Bayer's Xofigo (Radium Ra 223 Dichloride) for an elderly patient with late-stage prostate cancer

Valeant lead bidder for troubled Dendreon

Valeant lead bidder for troubled Dendreon prostate cancer market due in part to its high price, complex treatment process and competition from cheaper conventional drugs such as Johnson &Johnson's Zytiga (abiraterone) and Astellas/Medivation's

Dendreon to go to auction without initial bidder

Dendreon to go to auction without initial bidder Medivation's Xtandi(enzalutamide).

[ Previous 5 results ] 5 6 7 8 9 10 11 12 13 14 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cogora

Cogora has been a leader in healthcare publishing for over 30 years and has become one of the leading full-service...

Latest intelligence

Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...
The Future of Pharma sales: fast forward to 2029
Change is inevitable, and necessary, for growth in business....

Infographics